Congress

Frank Pallone

Politics

In public, lawmakers scold drug distributors. Come campaign season, they accept their cash willingly

Politics

Trump signs his first drug pricing bill — but whiffs on the details

By Nicholas Florko

advertisement

Utility pole

Pharmalot

A growing number of states consider legislation to treat pharma as a utility

By Ed Silverman

advertisement

Health Care Voters

First Opinion

Coverage for pre-existing conditions lives on, even though the Affordable Care Act seemed doomed

By David Blumenthal

Compounding - mortar and pestle

Politics

With safety and cash at stake, a squabble over drug compounding puts the FDA in a bind

By Nicholas Florko

Politics

A PAC is using the midterms to spotlight high drug prices. Why is it sinking millions into unwinnable races?

By Rebecca Robbins and Lev Facher

Medicine

Politics

A Republican lobbying firm is behind Washington’s newest pro-pharma advocacy group

By Nicholas Florko

advertisement

Prescription Medication

Politics

This brand-new advocacy group is an unapologetic defender of high drug prices

By Nicholas Florko

advertisement

Sen. Orrin Hatch

Politics

New bipartisan bill would give FDA the power to add off-label uses to generic drug labels

By Nicholas Florko

Pharmalot

Pharmalittle: Lilly will make its migraine drug free; FDA may get green light to allow imports

By Ed Silverman

Vials

Pharmalot

Pay-to-delay deals for biosimilars may be hard to pull off under a newly passed bill

By Ed Silverman

Pharmalot

Pharmalittle: AstraZeneca is accused of using nurses to promote drugs; Canada and U.S. spar over biologics exclusivity

By Ed Silverman

Planned Parenthood surreptitious video protest

Politics

Trump administration launches review of scientific research involving fetal tissue

By Megan Thielking

Mark Merritt

Politics

With PBMs firmly in Washington’s crosshairs, their top lobbyist steps down with no regrets

By Nicholas Florko

House Speaker Paul Ryan

Politics

Congress won’t include PhRMA-backed Medicare change in opioids package

By Nicholas Florko and Lev Facher

Pharmalot

Pharmalittle: Novartis employees brace for layoffs; FDA signals it will levy fines if trials aren’t reported

By Ed Silverman

Greg Walden and Frank Pallone

Politics

AMA urges Congress not to loosen restrictions on privacy for patients with addiction history

The US Capitol

Pharmalot

Senate bill to encourage generic drug development would yield $3.3 billion in savings

By Ed Silverman

Richard Durbin & Chuck Grassley

Politics

The latest roadblock to Trump’s plan to put drug prices in ads: House Republicans

By Nicholas Florko

Politics

Fact-checking an ad war over drug prices, Celgene, and Bob Hugin

By Damian Garde

President Obama Signs 21st Century Cures Act

First Opinion

Administrative delays threaten the promise of the 21st Century Cures Act

By Joel C. White

The Readout LOUD

LISTEN: A genome-editing flop, a Celgene Senate hopeful, and a live audience

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Bob Hugin - New Jersey Primary

Politics

The reinvention of Bob Hugin: Amid anger over drug prices, a former pharma CEO makes a run for the Senate

By Damian Garde

Carl H. June

Biotech

CAR-T pioneer on riding the NIH roller coaster, speaking up for science, and his funder Sean Parker

By Elizabeth Cooney

medication-assisted therapy

First Opinion

The Senate can change the course of the opioid crisis. Here are 50 ways it can do that

By Devin Oller

Kerri Evelyn Harris

Politics

Is mistrust of ‘big pharma’ enough to help unseat a Democratic stalwart in Congress?

Drug recovery center in Youngstown Ohio

Politics

The Senate could soon pass an opioids package. But a new law is still a long way away

Hospice patient

First Opinion

Fraud, waste, and abuse in the Medicare hospice program is ‘repellent’

By Joanne M. Chiedi

Pharmacy Benefit Managers illustration

Politics

The Trump administration can’t decide whether drug industry middlemen are the enemy — or part of the solution

By Ike Swetlitz